Becton, Dickinson and Company completed the spin-off Embecta.

Becton, Dickinson and Company, a global medical technology company, completed the spin-off Embecta, a diabetes care business, into an independent, publicly traded company. "The decision to spin off our Diabetes Care business is part of our active portfolio management and consistent with our BD 2025 strategy to Grow, Simplify and Empower," Tom Polen, BD Chairman, CEO and President.